All In Biotech

Drug Trial Radar · NCT02058160

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 736 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

736

Actual

Start

Jan 2014

Primary completion

Jul 2015

Study completion Jul 2015

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • Insulin glargine/lixisenatide (HOE901/AVE0010)Drug

    Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization. Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.

  • Insulin glargine (HOE901)Drug

    Insulin glargine was self-administered QD by SC injection at approximately the same time every day. After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).

  • Metformin (Background Drug)Drug

    Pharmaceutical form: Tablet; Route of administration: Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30Time frame: Baseline, Week 30

Locations

236 sites in 18 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840607

    Birmingham, Alabama

  • Investigational Site Number 840570

    Sun City, Arizona

  • Investigational Site Number 840562

    Tempe, Arizona

  • Investigational Site Number 840577

    Tucson, Arizona

  • Investigational Site Number 840517

    Little Rock, Arkansas

  • Investigational Site Number 840537

    Little Rock, Arkansas

  • Investigational Site Number 840568

    Bell Gardens, California

  • Investigational Site Number 840550

    Chino, California

  • Investigational Site Number 840529

    Chula Vista, California

  • Investigational Site Number 840623

    Corona, California

  • Investigational Site Number 840566

    Fresno, California

  • Investigational Site Number 840552

    Greenbrae, California

  • Investigational Site Number 840578

    Lancaster, California

  • Investigational Site Number 840626

    Los Angeles, California

  • Investigational Site Number 840581

    Los Angeles, California

  • Investigational Site Number 840621

    Mission Viejo, California

  • Investigational Site Number 840511

    Northridge, California

  • Investigational Site Number 840573

    Palm Springs, California

  • Investigational Site Number 840559

    Port Hueneme, California

  • Investigational Site Number 840536

    San Ramon, California

  • Investigational Site Number 840567

    Santa Ana, California

  • Investigational Site Number 840569

    Tarzana, California

  • Investigational Site Number 840572

    West Hills, California

  • Investigational Site Number 840582

    Aurora, Colorado

  • Investigational Site Number 840509

    Denver, Colorado

  • Investigational Site Number 840549

    Wilmington, Delaware

  • Investigational Site Number 840510

    Miami, Florida

  • Investigational Site Number 840521

    New Port Richey, Florida

  • Investigational Site Number 840602

    Ocala, Florida

  • Investigational Site Number 840538

    Ocoee, Florida

  • Investigational Site Number 840534

    Palm Harbor, Florida

  • Investigational Site Number 840594

    Atlanta, Georgia

  • Investigational Site Number 840614

    Columbus, Georgia

  • Investigational Site Number 840501

    Lawrenceville, Georgia

  • Investigational Site Number 840525

    Roswell, Georgia

  • Investigational Site Number 840588

    Idaho Falls, Idaho

  • Investigational Site Number 840580

    Arlington Heights, Illinois

  • Investigational Site Number 840519

    Chicago, Illinois

  • Investigational Site Number 840612

    Chicago, Illinois

  • Investigational Site Number 840556

    Springfield, Illinois

Showing 40 of 236 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.